Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phase 2VOQUEZNAPositive

AI Analysis

Summary

Phathom Pharmaceuticals completed patient enrollment ahead of schedule in the Phase 2 pHalcon-EoE-201 study of VOQUEZNA (vonoprazan) for eosinophilic esophagitis.

Clinical Trial Data

Phase

Phase 2

Importance:5/10

Sentiment:

0.60

clinical trialpatient enrollmentahead of schedulePhase 2

Related Companies

$PHAT

Read the original article

Published by yahoo_finance on June 23, 2026 11:59 AM

Read Original